ArticleCell reports. Medicine2025

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.

Stephane Champiat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.